Skip to main content
OpenTrials
Completed

NCT Number: NCT06614816

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years

Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

1 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Huaiyin District Center for Disease Control and Prevention

Huaian, Jiangsu, 223399, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ages ranging from 1 to 12 years for the general healthy population ;
  • Obtain informed consent from the volunteer and/or their legal guardian, and sign the informed consent form;
  • The volunteer and/or their legal guardian is able to comply with the requirements of the clinical trial protocol;
  • Axillary body temperature ≤37.0℃.

Exclusion criteria

  • Those who have previously been vaccinated against varicella, have a history of varicella or herpes zoster infection;
  • Allergy to known components of the study vaccine, or a history of severe allergic reactions to any vaccination;
  • A history of epilepsy, seizures, or convulsions, or a family history of psychiatric disorders;
  • Individuals with immunodeficiency, undergoing immunosuppressive therapy (e.g., oral corticosteroids), or HIV-related immunocompromised individuals, or those with family members closely exposed to congenital immune diseases;
  • Those with congenital malformations, developmental disorders, or severe chronic diseases (such as Down syndrome, diabetes, sickle cell anemia, neurological disorders, Guillain-Barré syndrome);
  • Known or suspected concurrent diseases, including respiratory diseases, acute infections, or active chronic diseases, cardiovascular diseases, skin diseases, severe hypertension, or during treatment for malignant tumors;
  • Diagnosed with coagulation dysfunction (e.g., deficiency of coagulation factors, coagulation disorders, platelet abnormalities) or significant bruising or coagulation disorders;
  • Receipt of blood products within the past 3 months;
  • Receipt of attenuated live vaccines within the past 14 days or subunit or inactivated vaccines within the past 7 days;
  • Acute illnesses or acute exacerbations of chronic diseases in the past 7 days;
  • A history of high fever (axillary body temperature ≥38.0℃) within the past 3 days;
  • Any other factors deemed by the investigator as unsuitable for participation in the clinical trial.

Treatment and study plan

Oka strain varicella attenuated live vaccine

Biological

lyophilized powder, subcutaneous injection

Primary outcomes

  1. seroconversion rate

    Time frame: 42 days after completing the full course of vaccination.

    The primary immunogenicity endpoint was the seroconversion rate of VZV antibodies

Secondary outcomes

  1. geometric mean titer (GMT)

    Time frame: 42 days after completing the full course of vaccination.

    geometric mean titer (GMT) of VZV antibodies 42 days after vaccination

  2. geometric mean fold increase (GMFI)

    Time frame: 42 days after completing the full course of vaccination.

    geometric mean fold increase (GMFI) of VZV antibodies 42 days after vaccination

Sponsors and collaborators

Lead sponsor

Southeast University, China

Other

Collaborators

  • Jiangsu CDC

Registry information

Official study title

Phase III Clinical Trial of Lyophilized Live Attenuated Varicella Vaccine for Children Aged 1-12 Years

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Sep 26, 2024
Registry last updated
Sep 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.